antibody

ERBB2 Polyclonal Antibody

MBS125445

0.05 mL

285 USD

polyclonal

rabbit

nonconjugated

human, mouse, rat

western blot, immunohistochemistry, immunocytochemistry, flow cytometry, FACS

Antibody

ERBB2 Polyclonal Antibody

ERBB2

HER2; ErbB2: ERBB2; CD340; HER-2; HER-2/neu; HER2; NEU; NGL; TKR1

Receptor tyrosine-protein kinase erbB-2; Receptor tyrosine-protein kinase erbB-2; receptor tyrosine-protein kinase erbB-2; herstatin; p185erbB2; proto-oncogene Neu; c-erb B2/neu protein; proto-oncogene c-ErbB-2; metastatic lymph node gene 19 protein; human epidermal growth factor receptor 2; neuro/glioblastoma derived oncogene homolog; tyrosine kinase-type cell surface receptor HER2; neuroblastoma/glioblastoma derived oncogene homolog; v-erb-b2 avian erythroblastic leukemia viral oncoprotein 2; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2; v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog; erb-b2 receptor tyrosine kinase 2; Metastatic lymph node gene 19 protein; MLN 19; Proto-oncogene Neu; Proto-oncogene c-ErbB-2; Tyrosine kinase-type cell surface receptor HER2; p185erbB2; CD_antigen: CD340

ERBB2

ERBB2; ERBB2; NEU; NGL; HER2; TKR1; CD340; HER-2; MLN 19; HER-2/neu; HER2; MLN19; NEU; NGL; MLN 19

ERBB2_HUMAN

Polyclonal

IgG

Rabbit

Human, Mouse, Rat

1255

Affinity Purification

1mg/ml

Store at -20 degree C (regular) or -80 degree C (long term). Avoid freeze / thaw cycles. Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3.

Western Blot (WB), Immunohistochemistry (IHC), Flow Cytometry (FC/FACS), Immunofluorescence (IF)

WB: 1:500 - 1:1000. IHC: 1:50 - 1:100. FC: 1:20 - 1:50. IF: 1:20-1:50

Species: Human. Route: Synthetic Peptide

Immunogen: A synthetic peptide of human ERBB2. Calculated Molecular Weight: 138kDa

Polyclonal

The ErbB2 (HER2) proto-oncogene encodes a 185 kDa transmembrane, receptor-like glycoprotein with intrinsic tyrosine kinase activity (1). While ErbB2 lacks an identified ligand, ErbB2 kinase activity can be activated in the absence of a ligand when overexpressed and through heteromeric associations with other ErbB family members (2). Amplification of the ErbB2 gene and overexpression of its product are detected in almost 40% of human breast cancers (3). Binding of the c-Cbl ubiquitin ligase to ErbB2 at Tyr1112 leads to ErbB2 poly-ubiquitination and enhances degradation of this kinase (4). ErbB2 is a key therapeutic target in the treatment of breast cancer and other carcinomas and targeting the regulation of ErbB2 degradation by the c-Cbl-regulated proteolytic pathway is one potential therapeutic strategy. Phosphorylation of the kinase domain residue Tyr877 of ErbB2 (homologous to Tyr416 of pp60c-Src) may be involved in regulating ErbB2 biological activity. The major autophosphorylation sites in ErbB2 are Tyr1248 and Tyr1221/1222; phosphorylation of these sites couples ErbB2 to the Ras-Raf-MAP kinase signal transduction pathway (1,5).

119533

P04626.1

P04626

1255

Adaptive Immune System Pathway (366160); Adherens Junction Pathway (83070); Adherens Junction Pathway (481); Alpha6-Beta4 Integrin Signaling Pathway (198807); Axon Guidance Pathway (105688); Bladder Cancer Pathway (83115); Bladder Cancer Pathway (527); Calcium Signaling Pathway (83050); Calcium Signaling Pathway (459); Central Carbon Metabolism In Cancer Pathway (1059538)

This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized. [provided by RefSeq, Jul 2008]

HER2: a proto-oncogenic receptor tyrosine kinase of the EGFR family. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. Not activated by EGF, TGF- alpha and amphiregulin. Amplified in breast cancer. Overexpression induces constitutive activity, and the gene is amplified or overexpressed in up to 30% of breast cancers, correlating with poor survival. The antibody Herceptin is approved for treatment of metastatic breast cancer with HER2 amplification/overexpression. Somatic mutations seen in 4% of lung cancers and also in breast, gastric, ovarian cancer and glioblastoma. One SNP shows predisposition to breast and gastric cancer. Inhibitors: Herceptin, lapatinib, PKI-166, EKB-569, CI-1033. Protein type: Protein kinase, tyrosine (receptor); Kinase, protein; Oncoprotein; Protein kinase, TK; Membrane protein, integral; EC 2.7.10.1; TK group; EGFR family. Chromosomal Location of Human Ortholog: 17q12. Cellular Component: perinuclear region of cytoplasm; basolateral plasma membrane; apical plasma membrane; cytoplasm; integral to membrane; plasma membrane; endosome membrane; cytoplasmic vesicle; nucleus; receptor complex. Molecular Function: protein dimerization activity; protein C-terminus binding; identical protein binding; transmembrane receptor protein tyrosine kinase activity; receptor signaling protein tyrosine kinase activity; protein phosphatase binding; protein binding; transmembrane receptor activity; ErbB-3 class receptor binding; protein heterodimerization activity; growth factor binding; protein-tyrosine kinase activity; ATP binding. Biological Process: myelination; axon guidance; phosphoinositide 3-kinase cascade; peptidyl-tyrosine phosphorylation; positive regulation of cell adhesion; wound healing; positive regulation of translation; nerve growth factor receptor signaling pathway; protein amino acid autophosphorylation; heart development; motor axon guidance; signal transduction; protein amino acid phosphorylation; enzyme linked receptor protein signaling pathway; positive regulation of transcription from RNA polymerase I promoter; positive regulation of MAP kinase activity; cell surface receptor linked signal transduction; oligodendrocyte differentiation; neuromuscular junction development; epidermal growth factor receptor signaling pathway; negative regulation of immature T cell proliferation in the thymus; regulation of microtubule-based process; phosphoinositide-mediated signaling; fibroblast growth factor receptor signaling pathway; transcription, DNA-dependent; regulation of angiogenesis; positive regulation of cell growth; peripheral nervous system development; cell proliferation; positive regulation of transcription from RNA polymerase III promoter; innate immune response; positive regulation of protein amino acid phosphorylation; transmembrane receptor protein tyrosine kinase signaling pathway; positive regulation of epithelial cell proliferation. Disease: Gastric Cancer; Lung Cancer; Glioma Susceptibility 1

0.05 mL

285 USD

0.2 mL

555